Concor Cor 1,25

Leaflet attached to the packaging: patient information

Warning! The leaflet should be kept. Information on the immediate packaging in a foreign language.

Concor Cor 1.25 (Concor COR 1.25 mg)

1.25 mg, coated tablets

Bisoprolol fumarate
Concor Cor 1.25 and Concor COR 1.25 mg are different trade names for the same medicine.

It is necessary to carefully read the contents of the leaflet before taking the medicine, as it contains important information for the patient.

• The leaflet should be kept so that it can be read again if necessary.
• In case of any doubts, the doctor or pharmacist should be consulted.
• This medicine has been prescribed to a specific person. It should not be given to others. The medicine may harm another person, even if the symptoms of their illness are the same.
• If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor, pharmacist, or nurse. See section 4.

Table of contents of the leaflet

• 1. What is Concor Cor 1.25 and what is it used for
• 2. Important information before taking Concor Cor 1.25
• 3. How to take Concor Cor 1.25
• 4. Possible side effects
• 5. How to store Concor Cor 1.25
• 6. Package contents and other information

1. What is Concor Cor 1.25 and what is it used for

The active substance of Concor Cor 1.25 is bisoprolol fumarate. Bisoprolol belongs to a group of medicines called beta-blockers. These medicines affect the body's response to certain nerve impulses, especially in the heart. As a result, bisoprolol slows down the heart rate and thus increases the efficiency of the heart in pumping blood within the body.
Heart failure occurs when the heart muscle is weak and cannot pump enough blood to meet the body's needs.
Concor Cor 1.25 is used to treat stable, chronic heart failure.

2. Important information before taking Concor Cor 1.25

When not to take Concor Cor 1.25

Concor Cor 1.25 should not be taken in the following cases:

• if the patient is allergic to bisoprolol or any of the other ingredients of this medicine (listed in section 6),
• if the patient has severe asthma,
• if the patient has serious blood circulation disorders in the limbs (such as Raynaud's syndrome), which can cause tingling, paleness, or bluish discoloration of the fingers or toes,
• if the patient has an untreated pheochromocytoma, a rare tumor of the adrenal gland,
• if the patient has metabolic acidosis, a condition in which the blood pH is abnormal,
• if the patient has acute heart failure,
• if the patient's heart failure worsens and requires intravenous administration of medicines that increase heart contractility,
• if the patient has symptoms of slow heart rate,
• if the patient has symptoms of low blood pressure,
• if the patient has certain heart diseases that cause very slow or irregular heartbeats (second or third degree atrioventricular block, sinoatrial block, sick sinus syndrome) without a pacemaker,
• if the patient has cardiogenic shock, a severe and life-threatening heart disorder that leads to low blood pressure and circulatory failure.

Warnings and precautions

If any of the following conditions occur, the patient should talk to their doctor before starting to take Concor Cor 1.25; the doctor may decide that special caution is necessary (e.g., additional medications or more frequent medical check-ups):

• diabetes,
• strict fasting,
• certain heart diseases (such as arrhythmias or severe chest pain at rest - Prinzmetal's angina),
• kidney or liver disorders,
• blood circulation disorders in the limbs,
• mild asthma or chronic obstructive pulmonary disease,
• psoriasis (psoriatic skin lesions), including a history of psoriasis,
• pheochromocytoma of the adrenal gland,
• thyroid function disorders.

In addition, the patient should tell their doctor if:

• desensitization treatment is planned (e.g., to avoid hay fever), as Concor Cor 1.25 may increase the risk of an allergic reaction or worsen such a reaction;
• a surgical procedure under general anesthesia is planned, as Concor Cor 1.25 may change the body's response to the administered medications.

Children and adolescents

Concor Cor 1.25 is not recommended for use in children and adolescents.

Concor Cor 1.25 and other medicines

The patient should tell their doctor about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take.
Concor Cor 1.25 should not be taken with the following medicines without special recommendation by the doctor:

• certain medicines used to treat arrhythmias (class I antiarrhythmic agents, such as quinidine, disopyramide, lidocaine, phenytoin, flecainide, propafenone);
• certain medicines used to treat high blood pressure, coronary artery disease, or arrhythmias (calcium channel blockers, such as verapamil and diltiazem);
• certain medicines used to treat high blood pressure, such as clonidine, methyldopa, moxonidine, rilmenidine. However, these medications should not be stopped without consulting a doctor.

Before taking the following medicines together with Concor Cor 1.25, the patient should talk to their doctor, as the doctor may recommend more frequent medical check-ups:

• certain medicines used to treat high blood pressure or coronary artery disease (calcium channel blockers of the dihydropyridine type, such as felodipine and amlodipine);
• certain medicines used to treat arrhythmias (class III antiarrhythmic agents, such as amiodarone);
• topically applied beta-blockers (such as eye drops for glaucoma treatment);
• certain medicines used to treat, for example, Alzheimer's disease or glaucoma (parasympathomimetics);
• medicines used to treat acute heart disorders (adrenergic agents, such as isoprenaline and dobutamine);
• insulin and oral antidiabetic agents;
• agents used in general anesthesia (e.g., during surgery);
• digitalis glycosides used to treat heart failure;
• non-steroidal anti-inflammatory agents (NSAIDs) used to treat arthritis, relieve pain, and reduce inflammation (e.g., ibuprofen and diclofenac);
• adrenaline, a medicine used to treat severe, life-threatening allergic reactions and cardiac arrest;
• all medicines that can lower blood pressure, either as a desired or undesired effect, such as antihypertensive agents, certain antidepressants (tricyclic antidepressants), certain antiepileptic agents, or agents used during general anesthesia (barbiturates), as well as certain medicines used in psychiatric disorders characterized by loss of contact with reality (phenothiazine derivatives);
• mefloquine, used to prevent and treat malaria;
• medicines used to treat depression, called monoamine oxidase inhibitors (except for MAO-B inhibitors);
• rifampicin, an antibiotic used to treat infections;
• ergotamine derivatives, medicines used to treat dementia and migraine headaches.

Pregnancy and breastfeeding

There is a risk that taking Concor Cor 1.25 during pregnancy may harm the baby.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a baby, they should consult their doctor or pharmacist before taking this medicine. The doctor will decide whether Concor Cor 1.25 can be taken during pregnancy.
It is not known whether bisoprolol passes into human milk, so breastfeeding is not recommended during treatment with Concor Cor 1.25.

Driving and using machines

The medicine may affect the ability to drive or use machines, depending on how it is tolerated. Special caution should be exercised at the beginning of treatment, after increasing the dose, or when changing medications, as well as when combining the medicine with alcohol.

3. How to take Concor Cor 1.25

This medicine should always be taken according to the doctor's recommendations. In case of doubts, the doctor or pharmacist should be consulted.
Regular medical check-ups are necessary during treatment with Concor Cor 1.25. This is especially important at the beginning of treatment, during dose increases, and when treatment is discontinued.
The tablet should be taken in the morning with food or on an empty stomach, with a glass of water. The tablets should not be chewed. Scored tablets can be divided into two equal doses.
Concor Cor 1.25 (1.25 mg), Concor Cor 2.5 (2.5 mg), Concor Cor 3.75 (3.75 mg), Concor Cor 5 (5 mg), Concor Cor 7.5 (7.5 mg), and Concor Cor 10 (10 mg) are available.

Adults

The doctor will start treatment with bisoprolol at a low dose, which will be gradually increased - the doctor will decide how to increase the dose. The recommended initial dose is 1.25 mg once daily.
The dose is increased at intervals of two weeks or more to 2.5 mg, 3.75 mg, 5 mg, 7.5 mg, and 10 mg once daily. This is usually done as follows:

• 1.25 mg of bisoprolol once daily for 2 weeks;
• 2.5 mg of bisoprolol once daily for 2 weeks;
• 3.75 mg of bisoprolol once daily for 2 weeks;
• 5 mg of bisoprolol once daily for 2 weeks;
• 7.5 mg of bisoprolol once daily for 2 weeks;
• 10 mg of bisoprolol once daily for maintenance (chronic) treatment.

The maximum recommended daily dose is 10 mg of bisoprolol.
Depending on how the medicine is tolerated, the doctor may recommend extending the time interval before the next dose increase. If the disease worsens or the medicine is not tolerated, it may be necessary to reduce the dose again or discontinue treatment. In some patients, a maintenance dose lower than 10 mg of bisoprolol may be sufficient.
The doctor will determine the appropriate course of action.

Liver or kidney function disorders

Special caution should be exercised when increasing the dose of Concor Cor 1.25.

Elderly patients

Dose adjustment is not necessary.

Use in children and adolescents

Concor Cor 1.25 is not recommended for use in children and adolescents.

Duration of treatment

Treatment with Concor Cor 1.25 is usually long-term.
If treatment needs to be discontinued, the doctor will usually recommend gradual reduction of the dose, otherwise, the disease may worsen.

Taking a higher dose of Concor Cor 1.25 than recommended

If a higher dose of Concor Cor 1.25 than recommended is taken, the doctor should be informed immediately. The doctor will decide what actions to take.
Symptoms of overdose include: slow heart rate, breathing difficulties, significant drop in blood pressure, dizziness, or seizures (caused by low blood sugar levels).

Missing a dose of Concor Cor 1.25

A double dose should not be taken to make up for a missed dose. The next morning, the recommended dose should be taken.

Discontinuing Concor Cor 1.25

Concor Cor 1.25 should never be discontinued without the doctor's recommendation. Otherwise, the disease may worsen.
In case of any further doubts about taking this medicine, the doctor or pharmacist should be consulted.

4. Possible side effects

Like all medicines, Concor Cor 1.25 can cause side effects, although not everybody gets them.
Very common(occurring in at least 1 in 10 patients):

• bradycardia (slow heart rate).

Common(occurring less frequently than 1 in 10 patients):

• worsening of existing heart failure,
• fatigue, asthenia (weakness), dizziness, headache,
• feeling of coldness or numbness in the hands or feet,
• low blood pressure,
• gastrointestinal disorders, such as nausea, vomiting, diarrhea, or constipation.

Uncommon(occurring less frequently than 1 in 100 patients):

• conduction disorders,
• sleep disorders,
• depression,
• bronchospasm (difficulty breathing) in patients with asthma or chronic obstructive pulmonary disease,
• muscle weakness or cramps.

Rare(occurring less frequently than 1 in 1,000 patients):

• hearing disorders,
• allergic rhinitis,
• reduced tear secretion (should be considered if the patient wears contact lenses),
• hepatitis, which can cause yellowing of the skin or eyes,
• changes in the results of certain blood tests, related to liver function (increased ALT and AST activity) or triglyceride levels in the blood,
• allergic reactions, such as itching, flushing, rash. The doctor should be contacted immediately if more severe allergic reactions occur, which may include: swelling of the face, neck, tongue, mouth, or throat, or difficulty breathing,
• impotence,
• nightmares, hallucinations,
• fainting.

Very rare(occurring less frequently than 1 in 10,000 patients):

• conjunctivitis (irritation or redness of the eyes),
• hair loss,
• onset or exacerbation of psoriatic skin lesions (psoriasis), psoriasis-like lesions.

Reporting side effects

If any side effects occur, including any side effects not listed in this leaflet, the doctor, pharmacist, or nurse should be informed. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products: Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl
Reporting side effects can help gather more information on the safety of the medicine.

5. How to store Concor Cor 1.25

The medicine should be stored out of sight and reach of children.
Concor Cor 1.25 should not be taken after the expiry date stated on the packaging. The expiry date refers to the last day of the month.
The medicine should not be stored at temperatures above 25°C.
Medicines should not be disposed of via wastewater or household waste. The pharmacist should be asked how to dispose of medicines that are no longer used. This will help protect the environment.

6. Package contents and other information

What Concor Cor 1.25 contains

• The active substance is bisoprolol fumarate. Each coated tablet contains 1.25 mg of bisoprolol fumarate.
• The other ingredients are: tablet core: colloidal anhydrous silica, magnesium stearate, crospovidone, pregelatinized starch, corn starch, microcrystalline cellulose, calcium hydrogen phosphate. tablet coating: dimethicone, talc, macrogol 400, titanium dioxide (E 171), hypromellose.

What Concor Cor 1.25 looks like and what the package contains

Concor Cor 1.25 mg is a white, round, coated tablet.
The package contains 30 or 60 coated tablets.
For more detailed information, the marketing authorization holder or parallel importer should be contacted.

Marketing authorization holder in Croatia, the country of export:

Merck d.o.o., Oreškovićeva 6 H/1, 10010, Zagreb, Croatia

Manufacturer:

Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany

Parallel importer:

Delfarma Sp. z o.o., ul. Św. Teresy od Dzieciątka Jezus 111, 91-222 Łódź

Repackaged by:

Delfarma Sp. z o.o., ul. Św. Teresy od Dzieciątka Jezus 111, 91-222 Łódź
Marketing authorization number in Croatia, the country of export: HR-H-350108325-01

Parallel import authorization number: 338/24

Date of leaflet approval: 09.09.2024

[Information about the trademark]